TheraRadar
← Back
Data updated: Jul 17, 2026

SAGE THERAP SUPERNUS

Pharma
Pharmaceuticals Execution: Good

SAGE THERAP SUPERNUS is a pharmaceutical company with 1 FDA-approved products.

2019
Since
1
Drugs
-
Trials
0
New Drugs (2yr)

FDA Novel Drug Designations

(2019)
1 Novel 1 First-in-Class 1 Breakthrough 1 Priority Review
See 1 novel approval →
2019 ZULRESSO (BREXANOLONE) First-in-Class · Breakthrough · Priority Review

SAGE THERAP SUPERNUS at a Glance

  • Fast trial execution (14 months median completion)

SAGE THERAP SUPERNUS's Key Drugs

SAGE THERAP SUPERNUS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

SAGE THERAP SUPERNUS's Recent FDA Approvals

New NDA/BLA approvals for SAGE THERAP SUPERNUS over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

SAGE THERAP SUPERNUS's Therapeutic Areas

Disease areas where SAGE THERAP SUPERNUS has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

SAGE THERAP SUPERNUS Pipeline Snapshot

Active clinical trials for SAGE THERAP SUPERNUS across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 14/19 completed
  • • Speed: 14 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges